论文部分内容阅读
目的 :探讨环孢霉素A在高危角膜移植手术后防治角膜移植排斥反应的疗效.方法 :对在我院施行穿透性及板层角膜移植术中属于高危角膜移植的病例共 2 4例 2 6只眼 ,其中≥ 9mm的大植片的有 12只眼 (占 5 0%) ,在术后 2 6只眼均用环孢霉素A口服及环孢霉素A液滴眼.结果 :角膜移植术后出现角膜排斥反应的有 10例 11只眼 (占 42 3%) ,经过治疗后角膜植片均透明 ,术后角膜移植片最终透明者有 2 4只眼 (占 92 3%) ,未见严重副作用.结论 :证明在高危角膜移植术后应用环孢霉素A治疗角膜移植排斥反应是确实有效.“,”Objective:To investigate the curative effect of cyclosporine A(CsA) in corneal transplantation by it′s prevention the corneal graft rejection.Methods:We observed 24 patients(26 eyes) with high-risk penetrating and lamellar keratoplasty,of these there were 12 eyes(50%) had corneal grafts≥9mm.CsA was started one week postoperatively.In all 26 eyes,CsA was given orally and also topically with 10% CsA salation daily.Results:11 eyes(42.3%) developed corneal graft rejection postoperatively,but the grafts cleared up after application of CsA.There were 24 eyes(92.3%) with clear grafts,and without any toxic or side effects.Conclusion:Cyclosporine A is effective and safe to prevent or cure the high-risk corneal graft rejection after keratoplasty.